Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
5.45 | 4.01% | 0.21 |
CPRX closed up 4.01 percent on Monday, October 21, 2019, on 43 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| See historical CPRX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Overbought Stochastic | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 4.01% | |
| Overbought Stochastic | Strength | 4.01% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.83% | |
| Narrow Range Bar | Range Contraction | 2.83% | |
| NR7 | Range Contraction | 2.83% | |
| Inside Day | Range Contraction | 2.83% | |
| Wide Bands | Range Expansion | 2.83% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 4.41% | |
| 20 DMA Support | Bullish | 4.41% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/23/2019
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Health Pharmaceutical Pharmaceutical Industry California Medication Disorders Virotherapy Health Sciences Epilepsy Pharmaceutical Sciences Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Tourette Syndrome Treatment Of Epilepsy
Health Pharmaceutical Pharmaceutical Industry California Medication Disorders Virotherapy Health Sciences Epilepsy Pharmaceutical Sciences Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Tourette Syndrome Treatment Of Epilepsy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CPRX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 7.67 |
| 52 Week Low | 1.85 |
| Average Volume | 2,392,039 |
| 200-Day Moving Average | 4.3009 |
| 50-Day Moving Average | 5.7059 |
| 20-Day Moving Average | 5.0513 |
| 10-Day Moving Average | 4.9845 |
| Average True Range | 0.3456 |
| ADX | 20.42 |
| +DI | 23.4313 |
| -DI | 21.348 |
| Chandelier Exit (Long, 3 ATRs ) | 5.6832 |
| Chandelier Exit (Short, 3 ATRs ) | 5.4468 |
| Upper Bollinger Band | 5.6696 |
| Lower Bollinger Band | 4.433 |
| Percent B (%b) | 0.82 |
| BandWidth | 24.480827 |
| MACD Line | -0.1361 |
| MACD Signal Line | -0.2242 |
| MACD Histogram | 0.0881 |
| Fundamentals | Value |
|---|---|
| Market Cap | 460.81 Million |
| Num Shares | 84.6 Million |
| EPS | -0.20 |
| Price-to-Earnings (P/E) Ratio | -27.25 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 6.97 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.88 | ||||
| Resistance 3 (R3) | 5.86 | 5.69 | 5.81 | ||
| Resistance 2 (R2) | 5.69 | 5.58 | 5.70 | 5.79 | |
| Resistance 1 (R1) | 5.57 | 5.51 | 5.63 | 5.59 | 5.76 |
| Pivot Point | 5.40 | 5.40 | 5.43 | 5.41 | 5.40 |
| Support 1 (S1) | 5.28 | 5.29 | 5.34 | 5.31 | 5.14 |
| Support 2 (S2) | 5.11 | 5.22 | 5.12 | 5.11 | |
| Support 3 (S3) | 4.99 | 5.11 | 5.09 | ||
| Support 4 (S4) | 5.02 |
